Pharmacogenetics of antidepressant response: an update.

Antonio Drago, Diana De Ronchi, Alessandro Serretti

Research output: Contribution to journalArticle

Abstract

The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances. This review focuses on the pharmacogenetics of the antidepressant response through the analysis and discussion of the most compelling evidence in this line of research. Online databases (Medline and PsycINFO) have been searched and the most replicated association findings relating to the genetics of the antidepressant response have been reported and discussed. Some replicated findings in the literature have suggested the serotonin transporter promoter (5-HTTLPR), serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), brain derived neurotrophic factor (BDNF), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) as putative regulators of the antidepressant response. A high rate of failure of replication has also been reported. Pharmacogenetics will hopefully provide the basis for personalised antidepressant treatment that is able to maximise the probability of a good response and to minimise side effects; however, this goal is not achievable at the moment. The extent of the validity of the replicated findings and the reasons for the poor results obtained from studies of the pharmacogenetics of the antidepressant response are discussed.

Original languageEnglish
Pages (from-to)257-274
Number of pages18
JournalHuman Genomics
Volume3
Issue number3
Publication statusPublished - Apr 2009

Fingerprint

Pharmacogenetics
Antidepressive Agents
Receptor, Serotonin, 5-HT1A
Corticotropin-Releasing Hormone Receptors
Receptor, Serotonin, 5-HT2A
Serotonin Plasma Membrane Transport Proteins
Brain-Derived Neurotrophic Factor
Databases
Research

ASJC Scopus subject areas

  • Drug Discovery
  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

Drago, A., De Ronchi, D., & Serretti, A. (2009). Pharmacogenetics of antidepressant response: an update. Human Genomics, 3(3), 257-274.

Pharmacogenetics of antidepressant response : an update. / Drago, Antonio; De Ronchi, Diana; Serretti, Alessandro.

In: Human Genomics, Vol. 3, No. 3, 04.2009, p. 257-274.

Research output: Contribution to journalArticle

Drago, A, De Ronchi, D & Serretti, A 2009, 'Pharmacogenetics of antidepressant response: an update.', Human Genomics, vol. 3, no. 3, pp. 257-274.
Drago A, De Ronchi D, Serretti A. Pharmacogenetics of antidepressant response: an update. Human Genomics. 2009 Apr;3(3):257-274.
Drago, Antonio ; De Ronchi, Diana ; Serretti, Alessandro. / Pharmacogenetics of antidepressant response : an update. In: Human Genomics. 2009 ; Vol. 3, No. 3. pp. 257-274.
@article{1ef2f3eba0964b87a33d3f9493a4fe92,
title = "Pharmacogenetics of antidepressant response: an update.",
abstract = "The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances. This review focuses on the pharmacogenetics of the antidepressant response through the analysis and discussion of the most compelling evidence in this line of research. Online databases (Medline and PsycINFO) have been searched and the most replicated association findings relating to the genetics of the antidepressant response have been reported and discussed. Some replicated findings in the literature have suggested the serotonin transporter promoter (5-HTTLPR), serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), brain derived neurotrophic factor (BDNF), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) as putative regulators of the antidepressant response. A high rate of failure of replication has also been reported. Pharmacogenetics will hopefully provide the basis for personalised antidepressant treatment that is able to maximise the probability of a good response and to minimise side effects; however, this goal is not achievable at the moment. The extent of the validity of the replicated findings and the reasons for the poor results obtained from studies of the pharmacogenetics of the antidepressant response are discussed.",
author = "Antonio Drago and {De Ronchi}, Diana and Alessandro Serretti",
year = "2009",
month = "4",
language = "English",
volume = "3",
pages = "257--274",
journal = "Human Genomics",
issn = "1473-9542",
publisher = "Henry Stewart Publications",
number = "3",

}

TY - JOUR

T1 - Pharmacogenetics of antidepressant response

T2 - an update.

AU - Drago, Antonio

AU - De Ronchi, Diana

AU - Serretti, Alessandro

PY - 2009/4

Y1 - 2009/4

N2 - The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances. This review focuses on the pharmacogenetics of the antidepressant response through the analysis and discussion of the most compelling evidence in this line of research. Online databases (Medline and PsycINFO) have been searched and the most replicated association findings relating to the genetics of the antidepressant response have been reported and discussed. Some replicated findings in the literature have suggested the serotonin transporter promoter (5-HTTLPR), serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), brain derived neurotrophic factor (BDNF), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) as putative regulators of the antidepressant response. A high rate of failure of replication has also been reported. Pharmacogenetics will hopefully provide the basis for personalised antidepressant treatment that is able to maximise the probability of a good response and to minimise side effects; however, this goal is not achievable at the moment. The extent of the validity of the replicated findings and the reasons for the poor results obtained from studies of the pharmacogenetics of the antidepressant response are discussed.

AB - The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances. This review focuses on the pharmacogenetics of the antidepressant response through the analysis and discussion of the most compelling evidence in this line of research. Online databases (Medline and PsycINFO) have been searched and the most replicated association findings relating to the genetics of the antidepressant response have been reported and discussed. Some replicated findings in the literature have suggested the serotonin transporter promoter (5-HTTLPR), serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), brain derived neurotrophic factor (BDNF), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) as putative regulators of the antidepressant response. A high rate of failure of replication has also been reported. Pharmacogenetics will hopefully provide the basis for personalised antidepressant treatment that is able to maximise the probability of a good response and to minimise side effects; however, this goal is not achievable at the moment. The extent of the validity of the replicated findings and the reasons for the poor results obtained from studies of the pharmacogenetics of the antidepressant response are discussed.

UR - http://www.scopus.com/inward/record.url?scp=65549122835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549122835&partnerID=8YFLogxK

M3 - Article

C2 - 19403460

AN - SCOPUS:65549122835

VL - 3

SP - 257

EP - 274

JO - Human Genomics

JF - Human Genomics

SN - 1473-9542

IS - 3

ER -